T he renin-angiotensin-aldosterone system (RAAS) has a central role in the physiology of blood pressure and is implicated in the pathogenesis of hypertension and cardiovascular disease. The RAAS cascade begins with the rate-limiting cleavage of angiotensinogen (AGT) by renin to produce angiotensin I (Ang I). 1 The subsequent conversion by the angiotensin-converting enzyme (ACE) of Ang I forms angiotensin II (Ang II) that is responsible for a broad range of physiological actions, many of which are mediated through the angiotensin receptor type 1 (AT 1 ), including vasoconstriction and the release of aldosterone from the adrenal glands. Ang II and aldosterone are the classical effectors of the RAAS with complementary actions to raise blood pressure. The enzymes, hormones, and receptors of the RAAS provide targets for effective therapies for hypertension and cardiovascular disease. They also have been popular candidates for genetic studies.
See Editorial by Brian J. Morris See Clinical PerspectiveSeveral reviews and meta-analyses summarize the vast number of studies of the RAAS genes in cardiovascular physiology, disease, and treatment. [2][3][4] Genes encoding renin (REN), angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin type 1 receptor (AGTR1), and aldosterone synthase (CYP11B2) feature prominently. Functional polymorphisms in these genes have been associated with significant variation in the levels of RAAS components including angiotensinogen, ACE, and renin.2 They have also been associated with high blood pressure and other cardiovascular diseases including coronary artery disease, preeclampsia and diabetic nephropathy. The results of gene studies of individual RAAS candidates have been heterogeneous in terms of the nature of the Background-Renin-angiotensin-aldosterone system genes have been inconsistently associated with blood pressure, possibly because of unrecognized influences of sex-dependent genetic effects or gene-gene interactions (epistasis). Methods and Results-We tested association of systolic blood pressure with single-nucleotide polymorphisms (SNPs) at renin (REN), angiotensinogen (AGT), angiotensin-converting enzyme (ACE), angiotensin II type 1 receptor (AGTR1), and aldosterone synthase (CYP11B2), including sex-SNP or SNP-SNP interactions. Eighty-eight tagSNPs were tested in 2872 white individuals in 809 pedigrees from the Victorian Family Heart Study using variance components models. Three SNPs (rs8075924 and rs4277404 at ACE and rs12721297 at AGTR1) were individually associated with lower systolic blood pressure with significant (P<0.00076) effect sizes ≈1.7 to 2.5 mm Hg. Sex-specific associations were seen for 3 SNPs in men (rs2468523 and rs2478544 at AGT and rs11658531 at ACE) and 1 SNP in women (rs12451328 at ACE). SNP-SNP interaction was suggested (P<0.005) for 14 SNP pairs, none of which had shown individual association with systolic blood pressure. Four SNP pairs were at the same gene (2 for REN, 1 for AGT, and 1 for AGTR1). The SNP rs3097 at CYP11B2 was represented...